NAMS Stock Analysis: Buy, Sell, or Hold?
NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares
$33.28
-1.98 (-5.62%)
▼
5d:
-4.64%
30d:
+13.47%
90d:
-4.26%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Smart Money Distribution
None View Scanner →
Strength: 3.8/10
Get Alerted When NAMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called NAMS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NAMS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: NAMS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: NAMS is currently trading at $33.28, which is considered fair relative to its 30-day fair value range of $30.33 to $34.75.
Technical Outlook: Technically, NAMS is showing sideways momentum. The price is currently testing key support at $32.58. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: NAMS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $49.50 (+48.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NAMS is showing sideways momentum. The price is currently testing key support at $32.58. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: NAMS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $49.50 (+48.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$30.33 -
$34.75
Company Quality Score
57/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
85.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 48.7% below Wall St target ($49.50)
Trading Range Analysis
30-Day Trading Range
$30.33 -
$34.75
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$3.39
(10.2%)
Support & Resistance Levels
Support Level
$32.58
Resistance Level
$37.37
Current Trend
Sideways
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.23
Wall Street Target
$49.50
(+48.7%)
Revenue Growth (YoY)
2.1%
Share & Embed Analysis
Last updated: July 13, 2026 9:29 PM ET
Data refreshes hourly during market hours. Next update: 10:29 PM
Data refreshes hourly during market hours. Next update: 10:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Louis G Lange
SELL
44619 shares
2026-03-11
Johannes Jacob Piete Kas…
SELL
101409 shares
2026-03-09
Johannes Jacob Piete Kas…
SELL
94124 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
Advanced NAMS Option Strategies
Professional options setups generated by AI based on today's NAMS price and gamma walls.
